Direkt zum Inhalt
Merck

N-059

Supelco

Norbuprenorphin -Lösung

1.0 mg/mL in methanol, ampule of 1 mL, certified reference material, Cerilliant®

Anmeldenzur Ansicht organisationsspezifischer und vertraglich vereinbarter Preise


About This Item

Empirische Formel (Hill-System):
C25H35NO4
CAS-Nummer:
Molekulargewicht:
413.55
UNSPSC-Code:
41116107
NACRES:
NA.24

Qualität

certified reference material

Qualitätsniveau

Form

liquid

Leistungsmerkmale

Snap-N-Spike®/Snap-N-Shoot®

Verpackung

ampule of 1 mL

Hersteller/Markenname

Cerilliant®

Konzentration

1.0 mg/mL in methanol

Methode(n)

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

Anwendung(en)

forensics and toxicology

Format

single component solution

Versandbedingung

wet ice

Lagertemp.

−20°C

SMILES String

CO[C@]12CC[C@@]3(C[C@@H]1[C@](C)(O)C(C)(C)C)[C@H]4Cc5ccc(O)c6O[C@@H]2[C@]3(CCN4)c56

InChI

1S/C25H35NO4/c1-21(2,3)22(4,28)16-13-23-8-9-25(16,29-5)20-24(23)10-11-26-17(23)12-14-6-7-15(27)19(30-20)18(14)24/h6-7,16-17,20,26-28H,8-13H2,1-5H3/t16-,17-,20-,22+,23-,24+,25-/m1/s1

InChIKey

YOYLLRBMGQRFTN-IOMBULRVSA-N

Suchen Sie nach ähnlichen Produkten? Aufrufen Leitfaden zum Produktvergleich

Allgemeine Beschreibung

Eine neue zertifizierte Dotierlösung®, geeignet für die Anwendung in der klinischen Toxikologie, forensischen Analytik oder Schmerzmittelüberwachung.

Rechtliche Hinweise

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
CERTIFIED SPIKING SOLUTION is a registered trademark of Cerilliant Corporation
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany

Ähnliches Produkt

Produkt-Nr.
Beschreibung
Preisangaben

Signalwort

Danger

Gefahreneinstufungen

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

Zielorgane

Eyes

Lagerklassenschlüssel

3 - Flammable liquids

WGK

WGK 1

Flammpunkt (°F)

49.5 °F - closed cup

Flammpunkt (°C)

9.7 °C - closed cup


Hier finden Sie alle aktuellen Versionen:

Analysenzertifikate (COA)

Lot/Batch Number

It looks like we've run into a problem, but you can still download Certificates of Analysis from our Dokumente section.

Wenn Sie Hilfe benötigen, wenden Sie sich bitte an Kundensupport

Besitzen Sie dieses Produkt bereits?

In der Dokumentenbibliothek finden Sie die Dokumentation zu den Produkten, die Sie kürzlich erworben haben.

Die Dokumentenbibliothek aufrufen

Marta Concheiro et al.
Therapeutic drug monitoring, 33(5), 619-626 (2011-08-24)
Buprenorphine is currently under investigation as a pharmacotherapy to treat pregnant women for opioid dependence. This research evaluates buprenorphine (BUP), norbuprenophine (NBUP), buprenorphine-glucuronide (BUP-Gluc), and norbuprenorphine-glucuronide (NBUP-Gluc) pharmacokinetics after high-dose (14-20 mg) BUP sublingual tablet administration in three opioid-dependent pregnant
Hong K Kim et al.
Pediatrics, 130(6), e1700-e1703 (2012-11-07)
Buprenorphine is a partial μ-opioid receptor agonist that is approved for the treatment of opioid dependency. It is generally believed to be safer than methadone because of its ceiling effect on respiratory depression. As more adults in US households use
Giuseppe Lippi et al.
Journal of clinical laboratory analysis, 25(4), 244-245 (2011-07-26)
Buprenorphine is a centrally acting analgesic drug that is administered for the management of opioid dependence and as an analgesic drug for the treatment of chronic pain. The growing use of this substance has determined an increased need for laboratory
Tor Seldén et al.
Forensic science international, 220(1-3), 284-290 (2012-05-09)
Buprenorphine is considered to have little respiratory side effects at therapeutic doses and the partial agonistic properties should produce a "ceiling effect" for respiratory depression at higher doses. Still, there are several reports on buprenorphine related deaths. Most deaths involve
Kenneth F Ilett et al.
Breastfeeding medicine : the official journal of the Academy of Breastfeeding Medicine, 7, 269-274 (2011-10-21)
The aim of the present study was to estimate the dose of buprenorphine and its primary metabolite norbuprenorphine that a breastfed infant would receive during maternal maintenance treatment with buprenorphine. Seven pregnant opioid-dependent women taking buprenorphine (median, 7 mg/day; range, 2.4-24 mg)

Protokolle

To optimize hydrolysis using β-glucuronidase, factors such as incubation time, temperature, hydrolysis pH, enzyme source, and enzyme concentration must be evaluated for each glucuronide metabolite to be analyzed.

Unser Team von Wissenschaftlern verfügt über Erfahrung in allen Forschungsbereichen einschließlich Life Science, Materialwissenschaften, chemischer Synthese, Chromatographie, Analytik und vielen mehr..

Setzen Sie sich mit dem technischen Dienst in Verbindung.